Caribou Biosciences (CRBU) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Voting matters and shareholder proposals
Election of three Class II directors to serve until the 2029 annual meeting, with nominees Andrew Guggenhime, David Johnson, and Nancy Whiting recommended for election.
Ratification of Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Approval sought for an amendment to the certificate of incorporation to provide for officer exculpation from certain fiduciary duty breaches as permitted by Delaware law.
Proposal to approve adjournment of the annual meeting if necessary to solicit additional votes or establish a quorum.
Proxies authorized to vote on any other business that may properly come before the meeting or any adjournments.
Board of directors and corporate governance
Board recommends all three director nominees for election to serve five-year terms.
Audit committee and external auditor matters
Deloitte & Touche LLP recommended for ratification as the external auditor for the upcoming fiscal year.
Latest events from Caribou Biosciences
- 2026 meeting covers director elections, auditor ratification, and officer exculpation proposals.CRBU
Proxy filing24 Apr 2026 - 2026 meeting covers director elections, auditor ratification, and officer exculpation amendment.CRBU
Proxy filing10 Apr 2026 - Pivotal trial planning advances for vispa-cel, with global commercialization and funding strategies outlined.CRBU
Leerink Global Healthcare Conference 202610 Mar 2026 - Strong clinical progress and improved financials position the pipeline for pivotal trials.CRBU
Q4 20255 Mar 2026 - Pivotal-ready allogeneic CAR-T therapies show strong efficacy, targeting broad patient access.CRBU
Citi’s 2026 Virtual Oncology Leadership Summit20 Feb 2026 - Allogeneic cell therapy innovators advance scalable, off-the-shelf treatments for autoimmune diseases.CRBU
Citi's 2024 Global Healthcare Conference3 Feb 2026 - Off-the-shelf CAR T therapy could transform lymphoma care by expanding access and curative potential.CRBU
The 67th American Society of Hematology (ASH) Annual Meeting3 Feb 2026 - CB-010 demonstrates robust efficacy and safety, with pivotal trials and new indications advancing.CRBU
Goldman Sachs 45th Annual Global Healthcare Conference1 Feb 2026 - CB-010 shows durable efficacy with partial HLA matching, supporting pivotal trials in 2025.CRBU
Jefferies 2024 Global Healthcare Conference1 Feb 2026